FierceBiotechOriginal article
{"a":[{"_":"Parabilis preps $413M IPO to fuel desmoid tumor drug into phase 3","$":{"href":"/biotech/parabilis-preps-413m-ipo-fuel-desmoid-tumor-drug-phase-3","hreflang":"en"}}]}
IPO/OfferingPositive
AI Analysis
Summary
Parabilis Medicines is preparing for an IPO expected to raise $413M-$476M to fund Phase 3 development of its desmoid tumor drug candidate.
Clinical Trial Data
Phase
3
Importance:6/10
Sentiment:
0.60
IPOPhase 3desmoid tumorfinancing
Read the original article
Published by FierceBiotech on June 4, 2026 9:47 AM